Alvotech and Finesse enter into biosimilars collaboration

Biosimilars/News | Posted 04/04/2014 post-comment0 Post your comment

Iceland-based biopharmaceutical company Alvotech and US-based bio-process management company Finesse Solutions (Finesse) announced on 14 March 2014 that they had entered into a partnership for bio-manufacturing.

138 AA011155

The collaboration will provide Alvotech with world-class, scalable, flexible and cost-efficient manufacturing and laboratory technology through the Finesse turnkey SmartFactory good manufacturing practice (GMP) manufacturing platform suite. SmartFactory is a single-use GMP bio-manufacturing capacity, which will allow Alvotech to rapidly expand its biosimilars business. Finesse, on the other hand, will benefit from gaining unprecedented access to Alvogen’s commercial, FDA approved, bio-manufacturing facility.

The collaboration, according to Alvotech CEO, Dr Andreas Herrmann, provides the company ‘with much-needed additional manufacturing capacity and scale-up capabilities’. This fits with the company’s ambitions to become a global leader in the biologicals industry. The first manufacturing suite is expected to be in place by the end of 2015.

The partnership also capitalizes on the flexibility afforded by Finesse’s SmartFactory, enabling the companies to implement cutting-edge, innovative solutions for established and development-stage biosimilars processes.

Alvotech is a sister company of US generics company Alvogen. The company offers its biologicals manufacturing capabilities to its partners and cooperates in the commercialization of its own developed biosimilar pipeline. Alvotech has invested US$250 million to build a plant in Reykjavik, Iceland, for the development and manufacture of a portfolio of biosimilar monoclonal antibodies [1], which is expected to open in early 2016.

Related article

Alvogen launches infliximab biosimilar in Europe


1.   GaBI Online - Generics and Biosimilars Initiative. Alvotech invests US$250 million in biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Apr 4]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
EC approval of first ustekinumab biosimilar Uzpruvo
Biosimilars/News Posted 16/01/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010